Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability
The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characteri...
Gespeichert in:
Veröffentlicht in: | AAPS PharmSciTech 2016-08, Vol.17 (4), p.932-939 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 939 |
---|---|
container_issue | 4 |
container_start_page | 932 |
container_title | AAPS PharmSciTech |
container_volume | 17 |
creator | Ochi, Masanori Kimura, Keisuke Kanda, Atsushi Kawachi, Takaki Matsuda, Akitoshi Yuminoki, Kayo Hashimoto, Naofumi |
description | The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and
1
H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration. |
doi_str_mv | 10.1208/s12249-015-0422-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1806080542</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1806080542</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</originalsourceid><addsrcrecordid>eNp9kUtPxCAUhYnR-P4BbgxLN1Wg0MfSjM9E4ySja0IpTNG2jEDjjL_Enyvz0LhydSH3nHNz8gFwgtE5Jqi48JgQWiYIswRRQpL5FtjHLEVJWaZk-897Dxx4_4oQSXGZ7oI9ktOU4bLYB1_jZuGNtLJRnZGihaKv4bgRrhPSvpleBSPhKP6FDMqZTxGM7aHV8LKzbtbYwcOJbU0Nr4yfKec320fV2nnM6-CHCQ287hvRS7VSedsOq5Cxs9ERFquTk2CdmKo4RWVaExZHYEeL1qvjzTwELzfXz6O75OHp9n50-ZDItMhDovMMV3VNS1prkSOsldBM06LSiiBWy1KXiFRUE1bIOqNZxiQpsryK5SljOUkPwdk6d-bs-6B84J3xUrWt6FVsx3GBMlQgRpdSvJZKZ713SvOZM51wC44RXwLhayA8AuFLIHwePaeb-KHqVP3r-CEQBWQt8HHVT5Xjr3Zwfaz8T-o3LICaqg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1806080542</pqid></control><display><type>article</type><title>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Ochi, Masanori ; Kimura, Keisuke ; Kanda, Atsushi ; Kawachi, Takaki ; Matsuda, Akitoshi ; Yuminoki, Kayo ; Hashimoto, Naofumi</creator><creatorcontrib>Ochi, Masanori ; Kimura, Keisuke ; Kanda, Atsushi ; Kawachi, Takaki ; Matsuda, Akitoshi ; Yuminoki, Kayo ; Hashimoto, Naofumi</creatorcontrib><description>The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and
1
H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration.</description><identifier>ISSN: 1530-9932</identifier><identifier>EISSN: 1530-9932</identifier><identifier>DOI: 10.1208/s12249-015-0422-x</identifier><identifier>PMID: 27435198</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Administration, Oral ; Animals ; Biochemistry ; Biological Availability ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Chemistry, Pharmaceutical ; Crystallization - methods ; Drug Compounding - methods ; Drug Stability ; Magnetic Resonance Spectroscopy - methods ; Male ; Pharmacology/Toxicology ; Pharmacy ; Polymers - chemistry ; Polymers - pharmacokinetics ; Polymethacrylic Acids - chemistry ; Rats ; Rats, Sprague-Dawley ; Research Article ; Solubility ; Spectrophotometry, Infrared - methods ; Thiazines - chemistry ; Thiazines - pharmacokinetics ; Thiazoles - chemistry ; Thiazoles - pharmacokinetics</subject><ispartof>AAPS PharmSciTech, 2016-08, Vol.17 (4), p.932-939</ispartof><rights>American Association of Pharmaceutical Scientists 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</citedby><cites>FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1208/s12249-015-0422-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1208/s12249-015-0422-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27435198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ochi, Masanori</creatorcontrib><creatorcontrib>Kimura, Keisuke</creatorcontrib><creatorcontrib>Kanda, Atsushi</creatorcontrib><creatorcontrib>Kawachi, Takaki</creatorcontrib><creatorcontrib>Matsuda, Akitoshi</creatorcontrib><creatorcontrib>Yuminoki, Kayo</creatorcontrib><creatorcontrib>Hashimoto, Naofumi</creatorcontrib><title>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</title><title>AAPS PharmSciTech</title><addtitle>AAPS PharmSciTech</addtitle><addtitle>AAPS PharmSciTech</addtitle><description>The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and
1
H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Biochemistry</subject><subject>Biological Availability</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Chemistry, Pharmaceutical</subject><subject>Crystallization - methods</subject><subject>Drug Compounding - methods</subject><subject>Drug Stability</subject><subject>Magnetic Resonance Spectroscopy - methods</subject><subject>Male</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Polymers - chemistry</subject><subject>Polymers - pharmacokinetics</subject><subject>Polymethacrylic Acids - chemistry</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Research Article</subject><subject>Solubility</subject><subject>Spectrophotometry, Infrared - methods</subject><subject>Thiazines - chemistry</subject><subject>Thiazines - pharmacokinetics</subject><subject>Thiazoles - chemistry</subject><subject>Thiazoles - pharmacokinetics</subject><issn>1530-9932</issn><issn>1530-9932</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUtPxCAUhYnR-P4BbgxLN1Wg0MfSjM9E4ySja0IpTNG2jEDjjL_Enyvz0LhydSH3nHNz8gFwgtE5Jqi48JgQWiYIswRRQpL5FtjHLEVJWaZk-897Dxx4_4oQSXGZ7oI9ktOU4bLYB1_jZuGNtLJRnZGihaKv4bgRrhPSvpleBSPhKP6FDMqZTxGM7aHV8LKzbtbYwcOJbU0Nr4yfKec320fV2nnM6-CHCQ287hvRS7VSedsOq5Cxs9ERFquTk2CdmKo4RWVaExZHYEeL1qvjzTwELzfXz6O75OHp9n50-ZDItMhDovMMV3VNS1prkSOsldBM06LSiiBWy1KXiFRUE1bIOqNZxiQpsryK5SljOUkPwdk6d-bs-6B84J3xUrWt6FVsx3GBMlQgRpdSvJZKZ713SvOZM51wC44RXwLhayA8AuFLIHwePaeb-KHqVP3r-CEQBWQt8HHVT5Xjr3Zwfaz8T-o3LICaqg</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Ochi, Masanori</creator><creator>Kimura, Keisuke</creator><creator>Kanda, Atsushi</creator><creator>Kawachi, Takaki</creator><creator>Matsuda, Akitoshi</creator><creator>Yuminoki, Kayo</creator><creator>Hashimoto, Naofumi</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160801</creationdate><title>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</title><author>Ochi, Masanori ; Kimura, Keisuke ; Kanda, Atsushi ; Kawachi, Takaki ; Matsuda, Akitoshi ; Yuminoki, Kayo ; Hashimoto, Naofumi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-f761bdd494dfa701feaf5f48bfe205dc9f902b4f258cd64665c2867b198455723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Biochemistry</topic><topic>Biological Availability</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Chemistry, Pharmaceutical</topic><topic>Crystallization - methods</topic><topic>Drug Compounding - methods</topic><topic>Drug Stability</topic><topic>Magnetic Resonance Spectroscopy - methods</topic><topic>Male</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Polymers - chemistry</topic><topic>Polymers - pharmacokinetics</topic><topic>Polymethacrylic Acids - chemistry</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Research Article</topic><topic>Solubility</topic><topic>Spectrophotometry, Infrared - methods</topic><topic>Thiazines - chemistry</topic><topic>Thiazines - pharmacokinetics</topic><topic>Thiazoles - chemistry</topic><topic>Thiazoles - pharmacokinetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ochi, Masanori</creatorcontrib><creatorcontrib>Kimura, Keisuke</creatorcontrib><creatorcontrib>Kanda, Atsushi</creatorcontrib><creatorcontrib>Kawachi, Takaki</creatorcontrib><creatorcontrib>Matsuda, Akitoshi</creatorcontrib><creatorcontrib>Yuminoki, Kayo</creatorcontrib><creatorcontrib>Hashimoto, Naofumi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>AAPS PharmSciTech</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ochi, Masanori</au><au>Kimura, Keisuke</au><au>Kanda, Atsushi</au><au>Kawachi, Takaki</au><au>Matsuda, Akitoshi</au><au>Yuminoki, Kayo</au><au>Hashimoto, Naofumi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability</atitle><jtitle>AAPS PharmSciTech</jtitle><stitle>AAPS PharmSciTech</stitle><addtitle>AAPS PharmSciTech</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>17</volume><issue>4</issue><spage>932</spage><epage>939</epage><pages>932-939</pages><issn>1530-9932</issn><eissn>1530-9932</eissn><abstract>The aim of the present study was to develop amorphous solid dispersion (ASD) of meloxicam (MEL) for providing rapid onset of action. ASDs of MEL with polyvinylpyrrolidone (PVP) K-30 (MEL/PVP), HPC-SSL (MEL/HPC), and Eudragit EPO (MEL/EPO) were prepared. The physicochemical properties were characterized by focusing on morphology, crystallinity, dissolution properties, stability, and the interaction of MEL with coexisting polymers. MEL/EPO was physicochemically stable after storage at 40°C/75% RH for 30 days. In contrast, recrystallization of MEL was observed in MEL/PVP and MEL/HPC at 40°C/50% RH for 30 days. Infrared spectroscopic studies and
1
H NMR analyses of MEL/EPO revealed that Eudragit EPO interacted with MEL and reduced intermolecular binding between MEL molecules. Intermolecular interaction of drug molecules is necessary for the formation of crystalline. Thus, the interaction of MEL with Eudragit EPO and interruption of the formation of supramolecular interaction between MEL molecules might lead to the inhibition of crystal growth of MEL. Of all the MEL solid dispersions prepared, MEL/EPO showed the largest improvement in dissolution behavior. Oral administration of MEL/EPO to rats showed rapid and enhanced MEL exposure with a 2.4-fold increase in bioavailability compared with crystalline MEL. Based on these findings, MEL/EPO was physicochemically stable and provided a rapid onset of action and enhanced bioavailability after oral administration.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27435198</pmid><doi>10.1208/s12249-015-0422-x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1530-9932 |
ispartof | AAPS PharmSciTech, 2016-08, Vol.17 (4), p.932-939 |
issn | 1530-9932 1530-9932 |
language | eng |
recordid | cdi_proquest_miscellaneous_1806080542 |
source | MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Administration, Oral Animals Biochemistry Biological Availability Biomedical and Life Sciences Biomedicine Biotechnology Chemistry, Pharmaceutical Crystallization - methods Drug Compounding - methods Drug Stability Magnetic Resonance Spectroscopy - methods Male Pharmacology/Toxicology Pharmacy Polymers - chemistry Polymers - pharmacokinetics Polymethacrylic Acids - chemistry Rats Rats, Sprague-Dawley Research Article Solubility Spectrophotometry, Infrared - methods Thiazines - chemistry Thiazines - pharmacokinetics Thiazoles - chemistry Thiazoles - pharmacokinetics |
title | Physicochemical and Pharmacokinetic Characterization of Amorphous Solid Dispersion of Meloxicam with Enhanced Dissolution Property and Storage Stability |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T12%3A22%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Physicochemical%20and%20Pharmacokinetic%20Characterization%20of%20Amorphous%20Solid%20Dispersion%20of%20Meloxicam%20with%20Enhanced%20Dissolution%20Property%20and%20Storage%20Stability&rft.jtitle=AAPS%20PharmSciTech&rft.au=Ochi,%20Masanori&rft.date=2016-08-01&rft.volume=17&rft.issue=4&rft.spage=932&rft.epage=939&rft.pages=932-939&rft.issn=1530-9932&rft.eissn=1530-9932&rft_id=info:doi/10.1208/s12249-015-0422-x&rft_dat=%3Cproquest_cross%3E1806080542%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1806080542&rft_id=info:pmid/27435198&rfr_iscdi=true |